Literature DB >> 17272399

Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2.

Nadder Sharif1, Louis Gendron, Julia Wowchuk, Philippe Sarret, Jean Mazella, Alain Beaudet, Thomas Stroh.   

Abstract

The somatostatin [somatotropin release-inhibiting factor (SRIF)] receptor subtypes sst(2A) and sst(5) are frequently coexpressed in SRIF-responsive cells, including endocrine pituitary cells. We previously demonstrated that sst(2A) and sst(5) exhibit different subcellular localizations and regulation of cell surface expression, although they have similar signaling properties. We investigated here whether sst(2A) and sst(5) functionally interact in cells coexpressing the two receptor subtypes. We stimulated both transfected cells stably expressing sst(2A) alone (CHO-sst(2A)) or together with sst(5) (CHO-sst(2A+5)) and the pituitary cell line AtT20, which endogenously expresses the two receptor subtypes, with either the nonselective agonist [D-Trp(8)]-SRIF-14 or the sst(2)-selective agonist L-779,976. In CHO-sst(2A) cells, stimulation with either ligand resulted in the loss of approximately 75% of cell surface SRIF binding sites and massive internalization of sst(2A) receptors. The cells were desensitized to subsequent stimulation with [D-Trp(8)]-SRIF-14, which failed to inhibit forskolin-evoked cAMP accumulation. Similarly, in CHO-sst(2A+5) and AtT20 cells, [D-Trp(8)]-SRIF-14 induced the loss of 60-70% of SRIF binding sites as well as massive sst(2A) endocytosis. By contrast, in cells expressing both sst(2A) and sst(5), selective stimulation of sst(2A) with L-779,976 resulted in only 20-40% loss of cell surface binding and markedly reduced sst(2A) internalization. Consequently, whereas CHO-sst(2A+5) and AtT20 cells stimulated with [D-Trp(8)]-SRIF-14 were desensitized to a second stimulation with the same agonist, cells prestimulated with L-779,976 were not desensitized to subsequent [D-Trp(8)]-SRIF-14 stimulation. These findings indicate that the presence of sst(5) in the same cells modulates trafficking and cell surface regulation of sst(2A) and cellular desensitization to the effects of SRIF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17272399     DOI: 10.1210/en.2006-1266

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

1.  Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors.

Authors:  Katja Kiseljak-Vassiliades; Mei Xu; Taylor S Mills; Elizabeth E Smith; Lori J Silveira; Kevin O Lillehei; Janice M Kerr; B K Kleinschmidt-DeMasters; Margaret E Wierman
Journal:  Mol Cell Endocrinol       Date:  2015-09-21       Impact factor: 4.102

2.  Characterization of agonist-dependent somatostatin receptor subtype 2 trafficking in neuroendocrine cells.

Authors:  Walaa Alshafie; Yingzhou Edward Pan; Hans-Jürgen Kreienkamp; Thomas Stroh
Journal:  Endocrine       Date:  2020-05-07       Impact factor: 3.633

3.  Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone (GH)-releasing hormone, and ghrelin in a nonhuman primate (Papio anubis).

Authors:  Jose Córdoba-Chacón; Manuel D Gahete; Justo P Castaño; Rhonda D Kineman; Raul M Luque
Journal:  Endocrinology       Date:  2011-11-22       Impact factor: 4.736

Review 4.  Pituitary somatostatin receptor signaling.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Trends Endocrinol Metab       Date:  2010-02-09       Impact factor: 12.015

5.  Phosphorylation of threonine 333 regulates trafficking of the human sst5 somatostatin receptor.

Authors:  Aline Petrich; Anika Mann; Andrea Kliewer; Falko Nagel; Anne Strigli; Jan Carlo Märtens; Florian Pöll; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2013-02-15

6.  In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.

Authors:  Federico Gatto; Federica Barbieri; Lara Castelletti; Marica Arvigo; Alessandra Pattarozzi; Francesca Annunziata; Alexandru Saveanu; Francesco Minuto; Lucio Castellan; Gianluigi Zona; Tullio Florio; Diego Ferone
Journal:  Pituitary       Date:  2011-06       Impact factor: 4.107

Review 7.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

Review 8.  Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

Authors:  Fatemeh G Amlashi; Nicholas A Tritos
Journal:  Endocrine       Date:  2016-01-21       Impact factor: 3.633

9.  Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization.

Authors:  Michael Grant; Haydar Alturaihi; Philippe Jaquet; Brian Collier; Ujendra Kumar
Journal:  Mol Endocrinol       Date:  2008-07-24

Review 10.  Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?

Authors:  Li-Chun Lin; Etienne Sibille
Journal:  Front Pharmacol       Date:  2013-09-09       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.